Reframe-O1: A Study To Investigate The Efficacy And Safety Of Luveltamab Tazevibulin Versus Investigator's Choice (Ic) Chemotherapy In Women With Ovarian Cancer (Including Fallopian Tube Or Primary Peritoneal Cancers) Expressing Folr1
Posted Date: Apr 26, 2024
- Investigator: Amanda Jackson
- Specialties: Cancer, Ovarian Cancer
- Type of Study: Drug
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
Criteria:
Null
Keywords:
Ovarian Cancer, Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer
For More Information:
Jessica Mullins
NULL
cancer@uchealth.com